Premium
Clinicopathological features of double‐hit B ‐cell lymphomas with MYC and BCL 2 , BCL 6 or CCND 1 rearrangements
Author(s) -
Yoshida Maki,
Ichikawa Ayako,
Miyoshi Hiroaki,
Kiyasu Junichi,
Kimura Yoshizo,
Arakawa Fumiko,
Niino Daisuke,
Ohshima Koichi
Publication year - 2015
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/pin.12335
Subject(s) - bcl6 , lymphoma , follicular lymphoma , chop , medicine , chemotherapy , cancer research , pathology , b cell lymphoma , diffuse large b cell lymphoma , b cell , germinal center , immunology , antibody
Double‐hit ( DH ) lymphomas are B ‐cell lymphomas characterized by chromosomal rearrangements, specifically of MYC and either BCL 2 , BCL 6 or CCND 1 . We reviewed 22 cases of DH lymphomas. BCL 2 / MYC DH lymphomas constituted the majority of these DH lymphomas (17 cases; 77%), followed by BCL 6 / MYC (2 cases; 9%) lymphomas. Assessing morphological features using the 2008 World Health Organization classification system, 15 cases (68%) were determined to be B ‐cell lymphoma, unclassifiable with features intermediate between diffuse large B ‐cell lymphoma ( DLBCL ) and Burkitt lymphoma ( BCLU ) (10 cases; 45%), or as DLBCL (5 cases; 23%), and 2 cases (9%) were classified as morphologically untransformed follicular lymphoma. Burkitt lymphoma was rare (1 case; 5%) among DH lymphomas. Nineteen cases were treated with R‐CHOP or a high dose chemotherapy regimen. After a median follow‐up of 11 months, 7 patients had died, and the 1‐year survival rate was 62.5%. High dose chemotherapy did not improve the outcome. We suggest that screening of genetic variations to detect DH lymphomas is required in diagnosing all lymphomas, even those determined morphologically to be follicular lymphoma.